News and Resources

Dexpramipexole Kv 7 Company News
01.16.19

Knopp Biosciences Expands Research Collaboration with Cincinnati Children’s to Characterize Effect of Dexpramipexole in Inflammatory Diseases

Discover this News
09.08.18

Editorial Accompanying Blood Cover Story Features Promise Of Dexpramipexole In Eosinophil-Associated Diseases

Discover this News
08.04.18

American Society of Hematology: “Dexpramipexole: a new antieosinophil drug?”

Discover this News
05.22.18

NIAID Now: Repurposed Drug Shows Promise for Treating Rare Eosinophilic Diseases

Discover this News
05.10.18

Knopp Biosciences Announces Publication of Phase 2 Trial Results of Dexpramipexole in Hypereosinophilic Syndromes (HES) in Blood

Discover this News
01.01.18

American Society of Hematology: “Dexpramipexole as an oral steriod-sparing agent in hypereosinophilic syndromes”

Discover this News
01.01.18

The Laryngoscope: “Dexpramipexole Depletes Blood and Tissue Eosinophils in Nasal Polyps”

Discover this News
09.06.17

Knopp Biosciences and APFED Announce Partnership to Advance Awareness of Hypereosinophilic Syndromes

Discover this News
01.16.17

Elsevier: “The targeted eosinophil-lowering effects of dexpramipexole in clinical studies”

Discover this News
1 2